These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. New developments in atherosclerosis: clinical potential of PCSK9 inhibition. Giunzioni I; Tavori H Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307 [TBL] [Abstract][Full Text] [Related]
30. PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. Handelsman Y; Lepor NE J Am Heart Assoc; 2018 Jun; 7(13):. PubMed ID: 29934421 [No Abstract] [Full Text] [Related]
31. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia. Stawowy P; Just IA; Kaschina E Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128 [TBL] [Abstract][Full Text] [Related]
32. PCSK9 inhibitors- A new age in lipid management? Grant PJ Diab Vasc Dis Res; 2017 May; 14(3):171. PubMed ID: 28467196 [No Abstract] [Full Text] [Related]
33. The efficacy of evolocumab in the management of hyperlipidemia: a systematic review. AlHajri L; AlHadhrami A; AlMheiri S; AlMutawa Y; AlHashimi Z Ther Adv Cardiovasc Dis; 2017; 11(5-6):155-169. PubMed ID: 28488460 [TBL] [Abstract][Full Text] [Related]
34. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Macchi C; Banach M; Corsini A; Sirtori CR; Ferri N; Ruscica M Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. Choi J; Khan AM; Jarmin M; Goldenberg N; Glueck CJ; Wang P Lipids Health Dis; 2017 Jul; 16(1):141. PubMed ID: 28738813 [TBL] [Abstract][Full Text] [Related]
36. Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials. Bays HE; Rosenson RS; Baccara-Dinet MT; Louie MJ; Thompson D; Hovingh GK Cardiovasc Drugs Ther; 2018 Apr; 32(2):175-180. PubMed ID: 29627892 [TBL] [Abstract][Full Text] [Related]
37. Alternative Treatment Regimens With the PCSK9 Inhibitors Alirocumab and Evolocumab: A Pharmacokinetic and Pharmacodynamic Modeling Approach. Scherer N; Dings C; Böhm M; Laufs U; Lehr T J Clin Pharmacol; 2017 Jul; 57(7):846-854. PubMed ID: 28263403 [TBL] [Abstract][Full Text] [Related]
38. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy. Koren MJ; Kereiakes D; Pourfarzib R; Winegar D; Banerjee P; Hamon S; Hanotin C; McKenney JM J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26586732 [TBL] [Abstract][Full Text] [Related]
39. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy? Cervelli N; Tocci G; Ferri C High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812 [No Abstract] [Full Text] [Related]
40. PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. Di Bartolo B; Scherer DJ; Brown A; Psaltis PJ; Nicholls SJ BioDrugs; 2017 Jun; 31(3):167-174. PubMed ID: 28424973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]